Abstract
Background: Total serum bilirubin (TSB) is used in managing neonates with jaundice, but clear evidence on its association with major outcomes is lacking. Objectives: We evaluated the association between TSB and kernicterus spectrum disorder (KSD). Methods: We searched PubMed, EMBASE, and CENTRAL till July 2021. Two authors independently selected relevant cohort studies, extracted data (CHARMS checklist), assessed risk of bias (RoB) (QUIPS tool), and rated certainty-of-evidence (Grades of Recommendation, Assessment, Development, and Evaluation). We pooled adjusted odds ratio (aOR) (random-effect) via generic inverse variance methods. Results: From 2,826 records retrieved, we included 37 studies (n = 648,979). Fifteen studies had low, 16 moderate, and 6 high RoB, with majority having concerns on confounder adjustment and statistical analysis. Twenty-two studies contributed meta-analysis data, and 15 were summarized narratively. TSB appears associated with KSD in infants with certain risk factors (aOR 1.10, 95% CI: 1.07–1.13; 5 studies [n = 4,484]). However, TSB (aOR 1.10, 95% CI: 0.98–1.23; 1 study [n = 34,533]) or hyperbilirubinemia (aOR 1.00, 95% CI: 0.51–1.95; 2 studies [n = 56,578]) have no clear association with kernicterus or neurological diagnosis in overall neonatal population (moderate-certainty-evidence). One study shows that infants with hyperbilirubinemia appear likelier to develop attention-deficit disorder (aOR 1.90, 95% CI: 1.10–3.28) and autistic spectrum disorder (aOR 1.60, 95% CI: 1.03–2.49, n = 56,019) (low-certainty-evidence). Certain clinical factors appear associated with KSD, although very few studies contributed to the analyses. Conclusions: Despite the importance of this question, there is insufficient high-quality evidence on the independent prognostic value of TSB for adverse neurodevelopmental outcomes in most neonatal populations. Future studies should incorporate all known risk factors alongside TSB in a multivariable analysis to improve certainty-of-evidence.
References
1.
Mitra
S
, Rennie
J
. Neonatal jaundice: aetiology, diagnosis and treatment
. Br J Hosp Med
. 2017
;78
(12
):699
–704
. .2.
Rennie
J
, Burman-Roy
S
, Murphy
MS
. Neonatal jaundice: summary of NICE guidance
. BMJ
. 2010
;340
:c2409
. .3.
Bhutani
VK
, Zipursky
A
, Blencowe
H
, Khanna
R
, Sgro
M
, Ebbesen
F
, Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels
. Pediatr Res
. 2013
;74
(Suppl 1
):86
–100
. .4.
Slusher
TM
, Zamora
TG
, Appiah
D
, Stanke
JU
, Strand
MA
, Lee
BW
, Burden of severe neonatal jaundice: a systematic review and meta-analysis
. BMJ Paediatr Open
. 2017
;1
(1
):e000105
. .5.
Chang
PW
, Newman
TB
, Maisels
MJ
. Update on predicting severe hyperbilirubinemia and bilirubin neurotoxicity risks in neonates
. Curr Pediatr Rev
. 2017
;13
(3
):181
–7
. .6.
Ahlfors
CE
. Predicting bilirubin neurotoxicity in jaundiced newborns
. Curr Opin Pediatr
. 2010
;22
(2
):129
–33
. .7.
Bhutani
VK
, Wong
RJ
. Bilirubin neurotoxicity in preterm infants: risk and prevention
. J Clin Neonatol
. 2013
;2
(2
):61
–9
. .8.
Shapiro
SM
. Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND)
. J Perinatol
. 2005
;25
(1
):54
–9
. .9.
Le Pichon
JB
, Riordan
SM
, Watchko
J
, Shapiro
SM
. The neurological sequelae of neonatal hyperbilirubinemia: definitions, diagnosis and treatment of the kernicterus spectrum disorders (KSDs)
. Curr Pediatr Rev
. 2017
;13
(3
):199
–209
. .10.
Shapiro
SM
, Riordan
SM
. Review of bilirubin neurotoxicity II: preventing and treating acute bilirubin encephalopathy and kernicterus spectrum disorders
. Pediatr Res
. 2020
;87
(2
):332
–7
. .11.
Shapiro
SM
, Powers
KM
. Kernicterus subtypes and their association with signs of neonatal encephalopathy
. Annals Neurol
. 2010
;68
:S117
–S8
.12.
Amin
SB
, Smith
T
, Timler
G
. Developmental influence of unconjugated hyperbilirubinemia and neurobehavioral disorders
. Pediatr Res
. 2019
;85
(2
):191
–7
. .13.
Alken
J
, Hakansson
S
, Ekeus
C
, Gustafson
P
, Norman
M
. Rates of extreme neonatal hyperbilirubinemia and kernicterus in children and adherence to national guidelines for screening, diagnosis, and treatment in Sweden
. JAMA Network Open
. 2019
;2
(3
):e190858
.14.
McGillivray
A
, Evans
N
. Severe neonatal jaundice: is it a rare event in Australia?
J Paediatr Child Health
. 2012
;48
(9
):801
–7
. .15.
Sgro
M
, Kandasamy
S
, Campbell
DM
, Ofner
M
. Comparing rate of severe neonatal hyperbilirubinemia in three Western industrialized populations: Canada, the United Kingdom & Ireland, and Switzerland
. Paediatr Child Health
. 2014
;19
(6
):e92
–e3
.16.
Greco
C
, Arnolda
G
, Boo
NY
, Iskander
IF
, Okolo
AA
, Rohsiswatmo
R
, Neonatal jaundice in low- and middle-income countries: lessons and future directions from the 2015 Don Ostrow trieste yellow retreat
. Neonatology
. 2016
;110
(3
):172
–80
. .17.
American Academy of Pediatrics Subcommittee on Hyperbilirubinemia
. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation
. Pediatrics
. 2004
;114
(1
):297
–316
. 18.
Amos
RC
, Jacob
H
, Leith
W
. Jaundice in newborn babies under 28 days: NICE guideline 2016 (CG98)
. Arch Dis Child Educ Pract Ed
. 2017
;102
(4
):207
–9
. .19.
Grohmann
K
, Roser
M
, Rolinski
B
, Kadow
I
, Müller
C
, Goerlach-Graw
A
, Bilirubin measurement for neonates: comparison of 9 frequently used methods
. Pediatrics
. 2006
;117
(4
):1174
–83
. .20.
Engle
WD
, Jackson
GL
, Engle
NG
. Transcutaneous bilirubinometry
. Semin Perinatol
. 2014
;38
(7
):438
–51
. .21.
Stevenson
DK
, Vreman
HJ
, Wong
RJ
. Bilirubin production and the risk of bilirubin neurotoxicity
. Semin Perinatol
. 2011
;35
(3
):121
–6
. .22.
Ip
S
, Chung
M
, Kulig
J
, O’Brien
R
, Sege
R
, Glicken
S
, An evidence-based review of important issues concerning neonatal hyperbilirubinemia
. Pediatrics
. 2004
;114
(1
):e130
–53
. .23.
Ip
S
, Chung
M
, Trikalinos
T
, DeVine
D
, Lau
JUS
. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Screening for Bilirubin Encephalopathy
. Rockville (MD)
: Agency for Healthcare Research and Quality (US)
; 2009
.24.
Ahlfors
CE
, Wennberg
RP
, Ostrow
JD
, Tiribelli
C
. Unbound (free) bilirubin: improving the paradigm for evaluating neonatal jaundice
. Clin Chem
. 2009
;55
(7
):1288
–99
. .25.
Guyatt
G
, Cairns
J
, Churchill
D
, Cook
D
, Haynes
B
, Hirsh
J
, Evidence-based medicine: a new approach to teaching the practice of medicine
. JAMA
. 1992
;268
(17
):2420
–5
.26.
Stroup
DF
, Berlin
JA
, Morton
SC
, Olkin
I
, Williamson
GD
, Rennie
D
, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group
. JAMA
. 2000
;283
(15
):2008
–12
. .27.
Connolly
AM
, Volpe
JJ
. Clinical features of bilirubin encephalopathy
. Clin Perinatol
. 1990
;17
(2
):371
–9
. .28.
Rosenbaum
PL
, Palisano
RJ
, Bartlett
DJ
, Galuppi
BE
, Russell
DJ
. Development of the gross motor function classification system for cerebral palsy
. Dev Med Child Neurol
. 2008
;50
(4
):249
–53
. .29.
Moons
KG
, Hooft
L
, Williams
K
, Hayden
JA
, Damen
JA
, Riley
RD
. Implementing systematic reviews of prognosis studies in Cochrane
. Cochrane Database Syst Rev
. 2018
;10
:ED000129
. .30.
Moons
KG
, de Groot
JA
, Bouwmeester
W
, Vergouwe
Y
, Mallett
S
, Altman
DG
, Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist
. PLoS Med
. 2014
;11
(10
):e1001744
. .31.
Hayden
JA
, van der Windt
DA
, Cartwright
JL
, Côté
P
, Bombardier
C
. Assessing bias in studies of prognostic factors
. Ann Intern Med
. 2013
;158
(4
):280
–6
. .32.
Grooten
WJA
, Tseli
E
, Äng
BO
, Boersma
K
, Stålnacke
BM
, Gerdle
B
, Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS-aspects of interrater agreement
. Diagn Progn Res
. 2019
;3
:5
. .33.
Reeves
BC
, Deeks
JJ
, Higgins
JPT
, Shea
B
, Tugwell
P
, Wells
GA
. Including non-randomized studies on intervention effects
. In: Higgins
JPT
, Thomas
J
, Chandler
J
, Cumpston
M
, Li
T
, Page
MJ
, , editors. Cochrane handbook for systematic reviews of interventions version 61 (updated September 2020)
: Cochrane
; 2020
. Available from. www.training.cochrane.org/handbook.34.
Review Manager 5.4
. The Cochrane Collaboration
; 2019
.35.
Debray
TP
, Damen
JA
, Snell
KI
, Ensor
J
, Hooft
L
, Reitsma
JB
, A guide to systematic review and meta-analysis of prediction model performance
. BMJ
. 2017
;356
:i6460
. .36.
Foroutan
F
, Guyatt
G
, Zuk
V
, Vandvik
PO
, Alba
AC
, Mustafa
R
, GRADE guidelines 28: use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks
. J Clin Epidemiol
. 2020
;121
:62
–70
. .37.
Lorio
A
, Spencer
FA
, Falavigna
M
, Alba
C
, Lang
E
, Bernard
B
, Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients
. Bri Med J
. 2015
;350
:h870
–h
.38.
McGuinness
LA
, Higgins
JPT
. Risk-of-bias visualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments
. Res Syn Meth
. 2020
.39.
Trikalinos
TA
, Chung
M
, Lau
J
, Ip
S
. Systematic review of screening for bilirubin encephalopathy in neonates
. Pediatrics
. 2009
;124
(4
):1162
–71
. .40.
Weng
YH
, Chiu
YW
, Cheng
SW
, Hsieh
MY
. Risk assessment for adverse outcome in term and late preterm neonates with bilirubin values of 20 mg/dL or more
. Am J Perinatol
. 2011
;28
(5
):405
–12
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
